Market Overview

Buy Accretive While On Weakness


JP Morgan has published a research report on Accretive Health (NYSE: AH) after the company reported revenue shortfalls in its 3Q.

In the report, JP Morgan writes "AH shares traded down 7.7% yesterday (vs. -0.4% for the S&P 500) after reporting 3Q EPS that was in line with consensus of $0.06, but revenue that was $14M below consensus of $172M. We believe the revenue miss sparked the selloff, and we view the decline as an overreaction to an otherwise good quarter."

JP Morgan maintains its Overweight rating but has lowered the price target from $27 to $22.

Accretive Health closed yesterday at $9.00.


Related Articles (AH)

View Comments and Join the Discussion!

Posted-In: accretive health JP MorganAnalyst Color Analyst Ratings

Latest Ratings

MRSNSVB LeerinkReiterates21.0
CTASB of A SecuritiesDowngrades
VICRBWS FinancialInitiates Coverage On84.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at